Effects of Sleep Quality on Functional and Cognitive Outcomes in Multiple Sclerosi

April 16, 2026 updated by: Büşra Seçkinoğulları Korkusuz

Effects of Sleep Quality on Cognitive Flexibility, Physical Activity, Body Awareness, and Reaction Time in Multiple Sclerosis

The goal of this observational study is to investigate the effects of sleep quality on cognitive flexibility, physical activity level, body awareness, and reaction time in individuals with Multiple Sclerosis.

The main question it aims to answer is:

Does sleep quality influence cognitive flexibility, physical activity level, body awareness, and reaction time in individuals with Multiple Sclerosis?

Researchers will compare individuals with good and poor sleep quality to determine whether differences in sleep quality result in variations in cognitive and physical performance outcomes.

Participants will complete standardized assessments of sleep quality, cognitive flexibility, physical activity, and body awareness, and will perform a computer-based reaction time test. In addition, participants will wear a wearable activity tracker for 7 days to objectively measure physical activity levels.

Study Overview

Status

Not yet recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

80

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The study population will consist of individuals aged 18-65 years who have been diagnosed with Multiple Sclerosis and are receiving routine care at the Department of Physical Therapy and Rehabilitation of Başkent University Hospital. Participants who meet the inclusion criteria and voluntarily agree to participate will be enrolled in the study.

Description

Inclusion Criteria:

  • Age between 18 and 65 years
  • Diagnosis of Multiple Sclerosis
  • Montreal Cognitive Assessment (MoCA) score ≥24
  • Expanded Disability Status Scale (EDSS) score between 0 and 6.5
  • No relapse within the last 3 months
  • Voluntary participation with written informed consent

Exclusion Criteria:

  • Presence of other neurological, psychiatric, or systemic diseases
  • Severe visual, auditory, or balance impairments
  • History of surgery within the last 6 months
  • Use of sleep medication or central nervous system-affecting drugs
  • Severe orthopedic deformity or pain

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Good Sleep Quality Group
Participants with Multiple Sclerosis who have a Pittsburgh Sleep Quality Index (PSQI) score of 5 or below, indicating good sleep quality.
Poor Sleep Quality Group
Participants with Multiple Sclerosis who have a Pittsburgh Sleep Quality Index (PSQI) score above 5, indicating poor sleep quality.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sleep Quality (Pittsburgh Sleep Quality Index)
Time Frame: Baseline
Sleep quality will be assessed using the Pittsburgh Sleep Quality Index. Total scores range from 0 to 21, with higher scores indicating poorer sleep quality.
Baseline
Cognitive Flexibility (Stroop Test, TBAG Form)
Time Frame: Baseline
Cognitive flexibility will be evaluated using the Stroop Test TBAG Form. Test completion time and number of errors will be recorded; longer completion times and more errors indicate lower cognitive flexibility.
Baseline
Physical Activity Level (International Physical Activity Questionnaire-Short Form)
Time Frame: Baseline
Physical activity level will be assessed using the International Physical Activity Questionnaire-Short Form. Total physical activity will be calculated in MET-min/week.
Baseline
Physical Activity Level (Wearable Device)
Time Frame: 7 days
Daily step count will be recorded using a wearable activity tracker. Average step count over 7 days will be calculated.
7 days
Body Awareness Questionnaire
Time Frame: Baseline
Body awareness will be evaluated using the Body Awareness Questionnaire. Higher scores indicate greater body awareness.
Baseline
Reaction Time (computer-based reaction time test)
Time Frame: Baseline
Reaction time will be assessed using a computer-based reaction time system. Average response time to visual stimuli will be recorded, with shorter times indicating better reaction performance.
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Büşra Seçkinoğulları Korkusuz

Collaborators

Atılım University
Baskent University Ankara Hospital

Investigators

  • Study Chair: Büşra S Korkusuz, Ankara University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

May 1, 2026

Primary Completion (Estimated)

July 1, 2026

Study Completion (Estimated)

August 1, 2026

Study Registration Dates

First Submitted

April 11, 2026

First Submitted That Met QC Criteria

April 11, 2026

First Posted (Actual)

April 17, 2026

Study Record Updates

Last Update Posted (Actual)

April 21, 2026

Last Update Submitted That Met QC Criteria

April 16, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • E-59394181-604.01-126829

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Multiple Sclerosis

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Rwanda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe